February 2, 2016 In an alarming shakeup to the HIV/AIDS community, the U.S. Congress dropped annual budget language that allocated 10% of the National Institutes of Health (NIH) yearly funding towards HIV/AIDS research. The sudden reallocation of resources for…
The 2016 elections will shape the work of many HIV prevention policy advocates as we continue to push for broader access to comprehensive services for all priority populations. With impending changes in federal and state leadership fast approaching, HIV advocates,…
RELATED: Toward Comprehensive HIV Prevention Service Delivery in the United States: An Action Plan December 18, 2015 A collaboration between Treatment Action Group and the HIV Prevention Justice Alliance, this webinar discusses the current state of the HIV prevention toolbox…
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
I would like to offer comments to correct the record on statements given by Senator Bill Cassidy (R-LA) at the October 7, 2015, hearing on the National Institutes of Health fiscal year 2016 budget. Several of his comments to the committee and NIH Director Francis Collins were incorrect or misleading. If his erroneous statements about AIDS research funding at the NIH are mistaken for fact, we will set a dangerous course for current and future research being conducted at the agency and undermine the prioritization process under way at the Office of AIDS Research (OAR).
Combination antiretroviral therapy (ART) is a highly effective treatment for HIV infection, preventing progression of the disease in the vast majority of recipients.
October 2015 Examples of media coverage: New Breakthrough May Lead to HIV Relapse Cure – Indo-Asian News Service, October 11, 2015 HIV breakthrough could lead to a CURE: Scientists identify markers on immune cells that ‘predict who can stop drug…
Supportive regulatory guidance for cure research requires a clear understanding of all possible outcomes, including remission By Richard Jefferys The term remission is increasingly being invoked in the context of cure research and, by extension, is an issue for regulatory…
Regulatory filing and review delays keep Truvada as pre-exposure prophylaxis out of reach of those who need it most By Scott Morgan Pre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent HIV acquisition. The U.S. Food and Drug…
In Defense of Stringency: In response to growing public concern with health risks posed by approved drugs, a 2006 landmark report by the Institute of Medicine (IOM) argued that the U.S. Food and Drug Administration (FDA) lacks the unambiguous authority necessary to ensure the safety and efficacy of the country’s medicinal products.